Before you sell to, join or invest in Grace Therapeutics, Inc.
MentionFox check on Grace Therapeutics, Inc.: only 1 source on file so far (checked 5 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/grace-therapeutics-inc-form-d-25000001
Check Grace Therapeutics, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about Grace Therapeutics, Inc.?
Based on the record MentionFox holds for this company. No flag is not a clearance.
Grace Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-02-25.
Grace Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on February 25, 2025. The filing reports $15M sold. Its industry group is Biotechnology. It names Prashant Kohli (Chief Executive Officer), Vimal Kavuru (Director), Robert J. DelAversano (Vice President, Finance, Principal Financial Officer and Principal Accounting Officer) (SEC Form D, February 25, 2025).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Grace Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-02-25 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Grace Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Grace Therapeutics, Inc., from the filings we hold.
TD Securities (USA) LLC received sales compensation on this raise and on 3 other raises we hold, nearest in date first:
Biotechnology raises by companies based in New Jersey, filed within 90 days of this one, largest first.
Get an email when Grace Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Grace Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Grace Therapeutics, Inc. →Get the full cited report on Grace Therapeutics, Inc.
What the filing shows about Grace Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Grace Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Grace Therapeutics, Inc.'s address as 103 Carnegie Center, Suite 300, Princeton, NJ 08540.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Grace Therapeutics, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Grace Therapeutics, Inc. See pricing
Grace Therapeutics, Inc. is a registered filer with the SEC (CIK 1444192) and has filed since 2023-10-10. 3 filings are on record, the latest on 2026-08-11.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Grace Therapeutics, Inc.'s Form D of 2025-02-25 names Prashant Kohli, Vimal Kavuru, Robert J. DelAversano and 6 more as its officers, directors or promoters.
Its new offerings report $32.50M sold across 3 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 765 filings in Biotechnology, totalled by week.
On the filing as: Director, Executive Officer.
Prashant Kohli is named as Chief Executive Officer on the Form D that Grace Therapeutics, Inc. filed with the SEC on 25 February 2025, one of 9 people that filing names.
Vimal Kavuru is named as Director on the Form D that Grace Therapeutics, Inc. filed with the SEC on 25 February 2025, one of 9 people that filing names.
On the filing as: Executive Officer.
Robert J. DelAversano is named as Vice President, Finance, Principal Financial Officer and Principal Accounting Officer on the Form D that Grace Therapeutics, Inc. filed with the SEC on 25 February 2025, one of 9 people that filing names.
A. Brian Davis is named as Director on the Form D that Grace Therapeutics, Inc. filed with the SEC on 25 February 2025, one of 9 people that filing names.
S. George Kottayil is named as Director on the Form D that Grace Therapeutics, Inc. filed with the SEC on 25 February 2025, one of 9 people that filing names.
Edward Neugeboren is named as Director on the Form D that Grace Therapeutics, Inc. filed with the SEC on 25 February 2025, one of 9 people that filing names.
On the filing as: Executive Officer.
Dr. R. Loch Macdonald is named as Chief Medical Officer on the Form D that Grace Therapeutics, Inc. filed with the SEC on 25 February 2025, one of 9 people that filing names.
On the filing as: Executive Officer.
Carrie D'Andrea is named as Vp Clinical Operations on the Form D that Grace Therapeutics, Inc. filed with the SEC on 25 February 2025, one of 9 people that filing names.
On the filing as: Executive Officer.
Amresh Kumar is named as Vp of Program Management on the Form D that Grace Therapeutics, Inc. filed with the SEC on 25 February 2025, one of 9 people that filing names.
9 people named on the filing — 5 holding an executive role and 4 as directors only.
Named as of the 2025-02-25 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Grace Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Grace Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Grace Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Grace Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Grace Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Grace Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Northern New Jersey
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/grace-therapeutics-inc-form-d-25000001